News & Views - Page 17 of 53 - Telix Pharmaceuticals Limited

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

Telix today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer.

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients.

Telix Announces Reorganisation to Deliver on Strategic Priorities

Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.

Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities

Telix today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated.

Telix Half-Year Results 2024 Investor Webcast Notification

Telix today advises that it will release its financial results for the half-year ended 30 June 2024 on Thursday 22 August 2024.

Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Telix today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara®1, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography (PET) agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration (FDA) agreement to proceed.

Telix has released an update to its Modern Slavery Statement

Modern slavery is a grave human rights violation involving various forms of exploitation, such as forced labour, human trafficking, debt bondage, forced marriage, and child exploitation. It affects millions globally, with recent estimates suggesting over 40 million people are trapped in modern slavery.

FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging1 for prostate cancer. The PDUFA2 goal date is March 24, 2025.

Telix Successfully Prices A$650 Million Convertible Bonds

Telix is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as “convertible bonds” (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary Shares). The Offering received strong support from eligible investors globally.

Telix Announces A$600 Million Convertible Bonds Offering

Telix today launches an offering of A$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as “convertible bonds” (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary Shares).